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Malignant glioma is the commonest primary neoplasm of the brain
and has a very poor prognosis. Although it rarely metastasises,
widespread local infiltration precludes complete surgical removal.
Following decompression, regrowth is rapid (Vertosick et al,
1994), suggesting that the remaining malignant tissue might be
particularly susceptible to cycle-specific drugs.
The Auger electron emission from 125I have an effective range
of only a few nanometers (Martin and Haseltine, 1981). Therefore
this radionuclide must be associated with DNA to kill cells (Kassis
et al, 1987). A suitable targeting vehicle is the thymidine analogue
5-[125I]iodo-2¢-deoxyuridine (i.e. [125I]IUdR) which is incorporated
into the DNA of cycling cells. Because of their rapid rate of
growth, there should be preferential uptake into tumour cells. The
efficacy of locoregional administration of this agent has been
demonstrated in rodent models of gliosarcoma (Kassis et al, 1998),
meningeal carcinoma (Kassis and Adelstein, 1996) and ovarian
ascites (Baranowska-Kortylewicz et al, 1991). Because [125I]IUdR
deiodinates rapidly in vivo (Klecker et al, 1985), it is anticipated
that non-intravenous routes of administration will be employed in
the initial clinical use of this agent.
Since nuclear incorporation of [125I]IUdR occurs only in cells
which are synthesizing DNA, a major limitation to this therapy is
the presence within the targeted tumour of cells which are
temporarily out of S phase during exposure to the drug
(O’Donoghue and Wheldon, 1996). One way to overcome this
restriction is to employ, in addition, radiohalogen conjugates of
deoxyuridine, such as the long range b-emitter 131I (Neshasteh-Riz
et al, 1998) or the a-emitter  211At (Larsen et al, 1997), whose
decay particles are lethal over ranges equivalent to several cell
diameters. By this approach, untargeted cells adjacent to those
which have accumulated radiopharmaceutical receive a radiation
dose by cross-fire. The potential benefit of this radiological
bystander effect has been demonstrated using multicellular tumour
spheroids (Cunningham et al, 1998; Neshasteh-Riz et al, 1998).
Alternative means of enhancing [125I]IUdR therapy of brain
tumours have also been illustrated by experimental targeted radio-
therapy (Neshasteh-Riz et al, 1997). Using a spheroid model, they
showed that by lengthening the time of incubation with [125I]IUdR
the cellular labelling index was increased due to the exposure of
larger numbers of cells passing through S phase. Micro-
encapsulation allows the preparation of biodegradable micro-
spheres that can be precisely implanted in a small area of the brain
by stereotactic techniques (Whateley et al, 1995; Menei et al,
1996; Reza and Whateley, 1998). IUdR can also be incorporated
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into thin films of biodegradable polymer (Reza and Whateley,
1999). Recently, the efficacy of continuous infusion of [125I]IUdR
by means of micro-osmotic pump was demonstrated using an in
vivo model system (Sahu et al, 1997). These findings suggest that
significant sparing of non-cycling malignant glioma cells would
result from treatment delivered as a single injection of [125I]IUdR
and that uptake of drug would be enhanced by prolonged expo-
sure. We have undertaken an investigation to test this hypothesis in
vivo. [125I]IUdR was administered directly into tumours produced
by intracerebral implantation in Wistar rats of C6 rat glioma cells.
Three different means of delivery were employed: single injection,
slow release from biodegradable inserts and diffusion from
implanted osmotic-pumps. We demonstrate that the tumour cell
uptake was greatly improved by prolonged delivery of the radio-
pharmaceutical and that the most efficient method was administra-
tion by osmotic-pump. Further development of biodegradable
implantation is required to optimize this approach.
MATERIALS AND METHODS
Materials
Tissue culture media and supplements were purchased from
Gibco-BRL (Paisley, UK). All other reagents were obtained from
Sigma-Aldrich Co Ltd (Dorset, UK), unless otherwise stated.
No-carrier-added [125I]IUdR of specific activity 74 TBq mmol–1
was obtained from Amersham International plc, UK.
Cell culture
The C6 rat glioma cell line was obtained from the American Type
Culture Collection (Rockville, MD, USA). Cells were grown in
F10-DMEM (Dulbecco’s modified Eagle’s medium) supple-
mented with 10% (v/v) fetal bovine serum. The cells were
passaged after reaching 90% confluency (every fourth day) and
plated at an initial density of 104 cells cm–2 at 37°C in 5% carbon
dioxide at 90% relative humidity. Cultures were routinely tested
and found to be free from mycoplasma contamination.
Experimental animals
All animal work was carried out in accordance with the UK
Coordinating Committee for Cancer Research guidelines on
experimental neoplasia in animals under the authority of a project
licence granted by the UK Home Office under the Animals
(Scientific Procedures) Act, 1986. Wistar male and female rats
weighing 250–300 g were obtained from Harlan Olac (Bicester,
UK).
Intracranial implantation of C6 cells
The implantation procedure was similar to those described previ-
ously (Kassis and Adelstein, 1996; Zhu et al, 1996). Briefly, after
the induction of anaesthesia by halothane inhalation, animals were
placed in a Kopf stereotaxic frame (Clarke Electromedical,
Reading, UK); the head was shaved and disinfected; a midline
incision was made using a scalpel blade and underlying tissue
removed using blunt dissection. Using a dentist drill fitted with a
size 018 burr (Wright Dental Group, Glasgow, UK) a hole was
drilled 4 mm posterior to the coronal suture and 3 mm to the right
of the sagittal suture. The needle was advanced to a depth of 6 mm
from the top of the skull and then withdrawn to a depth of
4 mm.
Exponentially growing C6 cells were detached from tissue
culture plates using 0.1% trypsin in phosphate-buffered saline
(PBS)–EDTA, suspended in PBS and counted in a Coulter counter
(Coulter Electronics, Luton, UK). Using a Hamilton syringe
(Hamilton, Bonaduz, Switzerland) fitted with a 23G needle,
5  ´ 104 cells contained in a 10 ml volume were injected slowly into
the cavity. After 1 min the needle was removed.
A piece of Surgicel (Johnson and Johnson, Livingston, UK) was
placed over the injection site to aid healing and prevent infection.
The head wound was then closed with Dexon sutures (Davis &
Geck, Gosport, Hants, UK). The procedure was carried out under
sterile conditions.
The animals were observed for three weeks. Those showing
signs of ill health or distress were immediately sacrificed.
Immunohistochemistry
The choice of time after implantation of C6 cells for assessment of
IUdR uptake was influenced by (a) the need to ensure a sufficient
interval for growth of an evaluable tumour mass; (b) the extent of
inflammatory cellular contamination; (c) the amount of necrotic
tissue, and (d) the toxic effect of excessive tumour growth. To
determine the time dependence of infiltration of inflammatory
cells into brain lesions, animals were sacrificed at various times
between 4 and 21 days after intracranial implantation of C6 cells.
Rat brains and control tissues (rat thymus and spleen) were fixed
in neutral buffered 4% formaldehyde for 24 h. The protocol for
each antibody was optimized in control tissues prior to labelling
the rat brains for the detection of T-cells, monocytes, macrophages
and B-cells.
T-cells
Sections were cut at 6 mm, mounted on to silane-coated slides and
baked overnight at 37°C. Sections were dewaxed and rehydrated
through standard solutions and endogenous peroxidase was
blocked with 3% hydrogen peroxide (H2O2) in methanol for
10 min. Antigen retrieval was carried out by boiling the sections in
10-mM citrate buffer pH 6.0 in a microwave oven for 10 min. After
cooling, sections were washed in PBS (10 mM sodium phosphate,
140 mM sodium chloride, pH 7.4); non-specific binding was
blocked with 20% normal goat serum for 10 minutes before the
primary antibody was applied (Rabbit anti-human T-cells CD3;
Dako Ltd, High Wycombe, UK) diluted to 1:400 in 10% normal
goat serum and incubated overnight at 4°C. Sections were washed
through 3 changes of PBS prior to application of the secondary
antibody (biotinylated goat anti-rabbit IgG diluted to 1:300 in 10%
normal goat serum, Dako Ltd) for 30 min. After 3 further washes
in PBS, the final layer was applied: avidin–biotin–peroxidase
complex (Vector Laboratories, Reading, UK). Sections were
developed in 0.05% diaminobenzidine-tetrahydrochloride, 0.01%
H2O2 for 10 min and labelling enhanced with 0.5% CuSO4.
Sections were lightly counterstained with haematoxylin, dehy-
drated through standard solutions and mounted in DPX.
Monocytes/macrophages
The procedure was similar to that described for the T-cells with a
few exceptions. Antigen retrieval was optimized with a 10-min
application of trypsin at 37°C (0.1% trypsin, 0.1% calcium
chloride in distilled water). Blocking serum was 2% bovine serum76 RJ Mairs et al
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albumin and the primary antibody was mouse anti-rat mono-
cytes/macrophages (ED1, Serotec, Oxford, UK) used at a 1:400
dilution with overnight incubation at 4°C. Biotinylated rabbit anti-
mouse immunoglobulins preabsorbed against rat immuno-
globulins (Dako Ltd) formed the second layer and the
avidin–biotin–peroxidase complex was applied as described for
the T-cells.
B-cells
The procedure for labelling rat B-cells was essentially similar to
the monocyte/macrophage protocol except that microwave antigen
retrieval was performed for a total of 20 min. The primary anti-
body, CD79a, was mouse anti-human B-cells (DAKO Ltd). This
was used at a dilution of 1:20 with overnight incubation at 4°C.
Determination of inflammatory cell infiltrate
Two independent observers evaluated T cell-, monocytes/
macrophage- and B-cell-specific staining in 4 central and 4
peripheral fields of 6 sections (10-mm thick) from individual
rat brains.
Biodistribution of [125I]IUdR
These experiments were performed on groups of six rats. To mini-
mize thyroidal uptake of free radioiodide, the drinking water was
supplemented with 0.1% (w/v) KI 2 days before administration of
[125I]IUdR.
One week after initiation of tumour growth and using the same
coordinates as those for implantation of C6 cells, rats were injected
intracranially with 0.37 MBq of [125I]IUdR in 10 ml. The injection
time was 1 min. After injection, the Hamilton syringe needle was
left in place for a further minute before being slowly withdrawn.
This procedure resulted in no leakage of injectate.
At various times (0.5, 1, 2, 24 and 48 h) after injection of radio-
pharmaceutical, the rats were killed. Tissues of interest were
removed, washed with PBS, blot-dried, weighed and the radio-
activity measured in an automated gamma counter (Canberra
Packard, Berkshire, UK). DNA was also isolated from these
tissues by phenol–chloroform extraction and the incorporated
radioactivity was determined by gamma counting. Statistical
analysis of biodistribution data was by Student’s t-test.
[125I]IUdR-loaded biodegradable thin films
Poly(D,L-lactic-co-glycolic acid) (PLGA), 85:15 (low intrinsic
viscosity, Mw 62 000), was purchased from Medisorb (Cincinnati,
OH, USA). PLGA was chosen for this work because of its clinical
acceptability and its biodegradable and biocompatible properties.
Carboplatin and etoposide have been incorporated into PLGA
implants and microspheres following studies which showed their
efficacy against the C6 glioma cell line (Whateley et al, 1995).
Thin films of [125I]IUdR were prepared by dissolving 10–30 mg
PLGA in dichloromethane, mixing in small volumes (5–20 ml) of
[125I]IUdR by sonication and casting into a small siliconized petri-
dish. The dichloromethane was allowed to evaporate overnight
and then dried at 40°C in a vacuum oven for 24 h. Radiolabelled
IUdR within the thin films has been shown to be protected from
degradation during incubation in PBS, serum and plasma (Reza
and Whateley, 1999).
Implantation of [125I]IUdR-loaded PLGA polymer
Thin films of PLGA for intracranial implantation had the dimen-
sions 2.5 ´ 1.5 ´ 0.19 mm. These were loaded with 0.37 MBq of
[125I]IUdR. Using a dentist drill, the existing hole in the skull of a
tumour-bearing rat was enlarged to a diameter of 2.5 mm. The
drilling was performed in short bursts and the skull cooled with
saline to prevent heat damage to the underlying brain. A fine
scalpel (No. 11) was used to make an incision in the dura at a depth
of 4 mm. The thin film was then gently lowered into this space.
Surgicel was then placed over the craniectomy site to protect the
exposed brain, prevent infection and aid healing. The wound was
then closed using Dexon sutures.
Implantation of osmotic pump
Alzet miniosmotic pumps (Charles River Ltd, Kent, UK) with a
capacity of 200 ml and a flow rate of 0.14 ml per min, were filled
with 200 ml of a solution containing 0.37 MBq of [125I]IUdR in
sterile saline, taking care to avoid the entrapment of air bubbles. A
brain infusion cannula was then attached to the pump and the
whole assembly incubated in sterile saline overnight at 37°C.
The scalp was washed, disinfected with chlorhexidine and a
midline incision was made. The underlying tissue was cleared
around the existing burr hole. A subcutaneous tunnel, leading from
the scalp incision to the midscapular space, was made using blunt
dissecting scissors. The pump was located in this space, with the
catheter tubing pointing towards the skull. A plastic spacer was
attached to the cannula before it was inserted into the burr hole to
achieve a depth of 4.5 mm. The cannula was attached to the skull
using Histoacryl (Cyanamid, Hampshire, UK). This was allowed
to harden for a few minutes before the scalp was closed with
Dexon sutures. This procedure was carried out under sterile
conditions.
Intracerebral distribution of [125I]IUdR
Twenty-four hours after the initiation of the administration of
0.37 MBq [125I]IUdR by intracranial single injection, polymer
implantation or osmotic pump delivery, animals were sacrificed.
Brains were prepared for sectioning and autoradiography by
freezing in isopentane (BDH, Poole, UK) cooled to –42°C for
10 min and then covering in Lipshaw embedding medium. They
were then stored at –20°C until required. After sectioning (10-mm
thick) and mounting, the slides were dipped in a 1:1 dilution of
Kodak NTB-2 emulsion in distilled water at 43°C. After drying,
the sections were exposed in light-proof desiccating boxes for
92 h. Sections were developed in 1:1 dilution of Kodak D 19
developer at 10°C for 4 min. After a brief wash in distilled water,
the emulsion was fixed in Kodafix for 5 min. The slides were
washed and couterstained with haematoxylin, dehydrated through
graded ethanols and mounted in DPX synthetic resin mountant
(BDH, Poole, UK).
To determine the depth within the tumour where maximal
uptake of [125I]IUdR had taken place, the tissue of every third
section was solubilized with 1 M sodium hydroxide and radio-
activity was measured in a gamma counter. For each experimental
animal, four sections, adjacent to the depth associated with peak
activity, were selected for the estimation of IUdR labelling indices.
Sections were examined using a Leitz microscope with a 10 ´ 10
square grid eyepiece graticule at 400´ magnification, providing aIntracranial IUdR for glioma treatment in rats 77
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square field measuring 0.26 ´ 0.26 mm (area = 0.068 mm2). Four
representative fields, at loci within the centre of the tumour mass,
were evaluated per section. Cells which had greater than ten
nuclear-associated grains were scored positively. The labelling
index for each field was calculated by expressing the number of
labelled cells as a percentage of all cells within the field, and the
mean labelling index for each animal was determined. For statis-
tical analysis, labelling indices were logarithmically transformed
to stabilize the variance in different treatment groups, and
compared by analysis of variance with Tukey’s method for
multiple pairwise comparisons.
RESULTS
Pathology
The basic histology of the lesion produced by intracranial implan-
tation of C6 cells was the same in all animals and comprised two
types of tissue. The first consisted of interlacing bundles of
spindle-shaped cells that had moderate nuclear to cytoplasmic
ratios, fairly dense nuclear chromatin with some mitotic figures
and rather indistinct cytoplasmic boundaries. The second cell type
comprised collections of small mononuclear cells, often perivas-
cular and with the appearance of lymphocytes and macrophages.
The C6 cells were negative for glial fibrillary acidic protein
(GFAP) and lymphocyte and macrophage markers. The mono-
nuclear population, as expected, marked positively for T-cells and
macrophages.
Four days after injection of C6 cells, the size of the lesion was
variable and in many cases difficult to distinguish from normal
brain. By 7 days, tumours had grown to at least 1.5 mm in diam-
eter and these could be clearly delineated. Larger lesions contained
substantial areas of necrosis and in some cases, haemorrhage had
occurred at the margins. After 2–3 weeks, some animals showed
signs of ataxia. These were immediately killed.
Inflammatory cell infiltrate
Although the C6 glioma cell line was derived from rat, we
observed in our rat model the migration of immune cells to the
tumour site. Figure 1 shows the pattern of T-cell-specific staining
associated with experimental tumour after 7 days of growth. The
distribution of monocyte/macrophage infitrate was similar to that
of T-cell distribution – i.e. the greatest concentration of immune
cells was at the margins rather than the central portions of the
malignant cellular mass. B-cells were absent from the brain
sections. After 7 days of tumour growth, T-cells and
monocytes/macrophages were evident mainly at the periphery of
lesions. In the centres of the tumours, inflammatory cells consti-
tuted approximately 6% of the total cellularity. On the basis of
these observations, we administered [125I]IUdR, directly into brain
lesions, 7 days after implantation of C6 cells. The evaluation of
tumour and normal brain uptake was performed 24 h after the initi-
ation of the delivery of the radiopharmaceutical.
Biodistribution
After intratumoural injection of [125I]IUdR, no toxicity was
observed in any animal. At 24 and 48 h, the retained fraction of
Table 1 Biodistribution data for a single intracranial injection of 0.37 MBq [125I]IUdR into normal (upper values) and tumour-bearing
(lower values) rats. Results are expressed as percent of injected dose per gram of tissue (mean ± s.d.); n = 6. s.d. values less than
0.005 were omitted
Time (h) 0.5 1.0 2.0 24.0 48.0
Organ
Brain 12.7±0.82 10.6±0.51 1.9±0.30 0.14±0.02c 0.13±0.02c
11.6±1.47 11.0±0.45 2.2±0.42 0.9±0.18 1.1±0.20
Blood 0.70±0.12 0.52±0.08 0.34±0.04 0.02±0.01 0.01
0.66±0.08 0.46±0.06 0.38±0.05 0.02±0.01 0.01
Thyroid 0.56±0.09 0.69±0.15 0.47±0.05c 0.44±0.06c 0.46±0.05
0.61±0.10 0.58±0.11 0.66±0.07 0.70±0.05 0.42±0.04
Liver 0.49±0.07 0.28±0.05 0.19±0.04 0.02±0.01 0.01
0.53±0.09 0.33±0.07 0.22±0.04 0.02±0.01 0.01
Small intestine 0.97±0.18 0.59±0.14 0.39±0.07b 0.20±0.05 0.07±0.02
1.12±0.23 0.67±0.10 0.30±0.06 0.24±0.05 0.08±0.02
Kidney 0.41±0.03 0.44±0.07 0.33±0.06 0.02±0.01 0.02±0.01
0.48±0.11 0.40±0.02 0.29±0.04 0.01 0.01
Stomach 1.83±0.22 2.07±0.38 1.05±0.08 0.37±0.09 0.12±0.02a
1.84±0.25 1.94±0.19 1.10±0.28 0.29±0.04 0.10±0.02
Bone marrow 0.20±0.03 0.19±0.03 0.16±0.02 0.03±0.01 0.03±0.01
0.22±0.04 0.17±0.02 0.18±0.03 0.03±0.01 0.03
Significance of difference between uptake in normal and tumour-bearing rats: aP < 0.05; bP < 0.01; cP < 0.001.
Figure 1 Typical immunocytochemical staining (brown) of T-cells infiltrating
7-day-old rat brain lesions induced by intracranial implantation of C6 cells78 RJ Mairs et al
British Journal of Cancer (2000) 82(1), 74–80 © 2000 Cancer Research Campaign
injected dose per gram of brain was significantly higher in tumour
bearing rats (P < 0.001). After 24 h, thyroid, stomach and, to a
lesser extent, small intestine were the only normal tissues exam-
ined which retained substantial amounts of radioactivity (Table 1).
The retention of activity by thyroid was significantly greater in test
animals than in control animals at 2 and 24 h (P < 0.001 for both
time points) after administration of radiopharmaceutical.
However, by 48 h, there was no significant difference between
thyroid activity in the two groups of rats. It is conceivable that
thyroid function could be altered by the presence of an intracranial
tumour which could vary the pressure experienced by pituitary or
other regulatory ganglia in the brain. This, is turn, could induce
variations in thyroid hormone output thereby effecting radio-
pharmaceutical uptake by thyroid in tumour-bearing rats.
We could detect no activity in DNA isolated from normal
tissues of either the test or control group of animals whereas in rats
with intracranial tumours, 24 h after injection of radiopharmaceu-
tical, 86.4 ± 2.4% (mean ± s.d.) of the activity associated with
brain was DNA-bound. This value increased to 90.1 ± 3.6% (mean
± s.d.) at 48 h. These observations are encouraging from the point
of view of therapy. However, the initial rapid loss of IUdR from
the brain emphasizes the need for a slow release delivery system.
IUdR labelling index of experimental tumours
All three delivery systems were well tolerated by the animals;
none of the animals exhibited sign of either discomfort or distress.
The animals were sacrificed 24 h after the initiation of the admin-
istration of [125I]IUdR. At this time, the remaining activity associ-
ated with PLGA polymer was, in all cases, less than 9% of the
loaded dose. The corresponding residual activity in the osmotic
pump reservoirs was less than 6% of the loaded dose. From dual
labelling pilot studies (autoradiography and immunohistochem-
istry) it was clear that the immunohistochemical label could not be
visualized underneath the silver grains of cells with heavy IUdR
uptake. Therefore unequivocal identification of radiolabelled cells
expressing leucocyte-specific antigens was not possible. Because
the immune cells associated with the intracranial C6 lesions were
located mainly at the periphery of the malignant cellular mass,
labelling indices were assessed in regions within the body of the
tumour.
Autoradiograms of brain sections demonstrated nuclear uptake
of the radiopharmaceutical in cells throughout tumour, while
normal brain cells remained free from radioactivity. The
[125I]IUdR labelling indices (% ± s.e.m.) achieved were 6.2 (0.4)
Figure 2 Autoradiograms of sections of 7-day-old C6 tumours exposed to
0.37 MBq [125I]IUdR using alternative delivery methods: (A) single
intralesional injection; (B) slow-release PLGA polymer implant;
(C) mini-osmotic pump
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by single injection, 22.5 (4.1) by slow-release polymer implant
(polylactide-glycolide) and 34.3 (2.0) by mini-osmotic pump
(Figures 2 and 3). These differences were all statistically signifi-
cant (pump versus single injection, P < 0.001; polymer implant
versus single injection, P < 0.001; pump versus polymer implant,
P < 0.05).
DISCUSSION
Auger electron emitters, such as 125I, are radiotoxic only to cells
which incorporate them into DNA (Kassis et al, 1987). This is
because the effective range of Auger electrons is only a few
nanometers (Martin and Haseltine, 1981). The thymidine analogue
[125I]IUdR facilitates the delivery of lethal radiation to dividing cells
while sparing quiescent cells. Therefore there is considerable
interest in the intralesional delivery of this radiopharmaceutical for
the treatment of residual glioma following surgery (Kassis et al,
1996). However, it is recognized that a limitation of short-term
administration of [125I]IUdR would be sparing of malignant cells not
involved in DNA synthesis during the time of exposure to the drug.
In a previous study, using a multicellular tumour spheroid
model, we demonstrated that prolongation of incubation time
increased cellular accumulation of [125I]IUdR (Neshasteh-Riz et al,
1997). This suggested that protracted delivery of the radiopharma-
ceutical may be used to overcome the difficulty caused by prolifer-
ative heterogeneity of gliomas. Brem and co-workers (Brem et al,
1995; Olivi et al, 1996; Sipos et al, 1997) have pioneered the use
of sustained release biodegradable polymeric implants containing
cytotoxic agents (e.g. carmustine) for the treatment of brain
tumours and it has been demonstrated that synthetic implantable,
biodegradable polymers hold promise for the controlled release
and local delivery of IUdR for radiosensitization of gliomas
(Williams et al, 1997). In a recent study involving a rat model of
leptomeningeal metastases, continuous infusion of [125I]IUdR by
means of micro-osmotic pump was found to be more effective than
single or intermittent applications of the radiopharmaceutical
(Sahu et al, 1997).
The present investigation was designed to compare the extent of
cellular uptake of [125I]IUdR in experimental tumours achieved by
single intralesional injection, slow-release polymer implant and
diffusion from osmotic pump. We have demonstrated that signifi-
cantly greater accumulation of [125I]IUdR was achieved in malig-
nant cells by means of sustained delivery than by single
intralesional injection and that administration by osmotic pump
was superior to release from a biodegradable implant. This
confirms our previous findings of enhancement of [125I]IUdR
uptake in vitro, by prolonged exposure of glioma cell monolayers
and spheroids (Neshasteh-Riz et al, 1997) and is in agreement with
the previously observed superiority of osmotic pump delivery
(Sahu et al, 1997). Recent studies have shown that in vitro there is
a rapid release of 40% IUdR in 4 h followed by a slow sustained
loss of drug. However, the rate of release of IUdR from PLGA thin
films can be finely regulated by varying the thickness of the
polymer (Reza and Whateley, 1999). Further refinements to the
design of this delivery system are in progress to achieve sustained
release of IUdR over a range of time intervals. Extension of the
infusion time beyond 24 h to several days should enable greater
enhancement of radiopharmaceutical uptake in tumour provided
radiolabelled IUdR remains stable. The effectiveness of this
approach can be determined using in vivo models (Sahu et al,
1997).
Despite the supposed syngeneity of the tumour cell line
employed in our model, an inflammatory infiltrate (T-cells,
macrophages and monocytes) was apparent after seven days in
regions of the brain adjacent to the site of the malignant lesion.
Nonetheless, the density of inflammatory cells in central regions
was sufficiently low to allow an evaluation of [125I]IUdR uptake
into C6 cells. The presence of significant anti-tumour immunity
following experimental treatment suggests that the immune
system could play a critical role and that the success of novel ther-
apies could be improved by better understanding the part played
by the host’s immunity. However, a recent study has shown that
C6 cells are allogeneic in several strains of rat (Beutler et al,
1999), suggesting that the C6 model may not be useful for experi-
mental therapy.
Twenty-four hours after intratumoural injection of [125I]IUdR,
99% of the activity observed after 30 min had cleared from the
brains of control animals whereas nuclear uptake occurred in the
brains of tumour-bearing animals. After intratumoural injection of
[125I]IUdR, no toxicity was apparent and the greatest accumulation
of the radiopharmaceutical after 48 h occurred in tumour. Activity
was evident in the thyroid (indicating incomplete blockade by
potassium iodide), in the stomach and small intestine after 2 days.
The latter observation is in agreement with pharmacokinetic
studies using a rat brain tumour model derived from the rat glioma
cell line 9L (Kassis et al, 1990; Kassis and Adelstein, 1996).
Encouragingly, concentration of [125I]IUdR did not occur in bone
marrow.
Heterogeneous proliferative activity of glioma cells is one of the
main barriers to the therapeutic use of radiolabelled IUdR. In a
previous study of an alternative approach to the eradication of
non-cycling malignant cells, we compared the in vitro toxicities of
three radioiodoanalogues of IUdR. Ultra-short range Auger elec-
tron emitters (125I and 123I) coupled to IUdR were more toxic than
[131I]IUdR to clonogens derived from single cell cultures and
treated in exponential growth phase. In contrast, the long-range
b-emitter conjugate [131I]IUdR, which provides some ‘cross fire’
irradiation between cells, was more efficient than the short-range
radionuclides in reducing the survival of clonogens derived from
multicellular spheroids (Neshasteh-Riz et al, 1998). It was
concluded that only cells which were in S phase during the period
of incubation with radiopharmaceutical were killed by IUdR
conjugated to Auger electron emitters (123I and 125I), whereas
[131I]IUdR had superior toxicity to clonogenic cells in spheroids
due to cross-fire b-irradiation of G0 cells. These findings suggest
that a combination of [131I]IUdR and [125I]IUdR or [123I]IUdR
might be more effective than [125I]IUdR or [123I]IUdR alone for the
treatment of residual glioma. It is also important to recognize that
in the setting of immediate post-surgical resection, regrowth is
rapid (Cruickshank, 1997) and a large fraction of cells are actively
replicating. In this situation an S phase-specific agent would be
valuable, especially if administered by a slow delivery system.
Another means of overcoming the incomplete dose distribution
associated with 125I therapy has been demonstrated using the a-
emitter conjugate 5-[211At]astato-2¢-deoxyuridine ([211At]AUdR)
(Vaiyanathan et al, 1996). Not only does tumour cell uptake of
211At enable alpha particle bombardment of neighbouring, untar-
geted, out-of-cycle cells by cross-fire but each decay of 211At
produces at least ten times the number of DNA double-strand
breaks as that obtained per 125I decay (Walicka et al, 1998). The
optimal therapeutic use of radiolabelled deoxyuridine may consist
of mixtures of short- and long-range radionuclide derivatives80 RJ Mairs et al
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including [125I]IUdR, [131I]IUdR, [211At]AUdR and [123I]IUdR. The
latter agent, as well as delivering toxic Auger electrons to tumour
cells, could, by virtue of its favourable g-emissions, facilitate
imaging to direct external beam irradiation.
In conclusion, we have studied a variety of methods of intra-
cerebral delivery of IUdR to determine which procedure would
result in the maximal tumour uptake. Direct injection, implantable
osmotic pumps and biodegradable polymers were used to admin-
ister [125I]IUdR. Autoradiography of brain sections demonstrated
nuclear uptake of the radiopharmaceutical in cells throughout
tumour while normal brain cells remained free from radioactivity.
Labelling was optimal for the pump delivering a given load over
24 h and was substantially better than for a single injection. These
results reinforce our in vitro findings and emphasize the need for a
protracted delivery system (perhaps extending over several days
provided this is within the limits of the stability of [125I]IUdR) as a
prerequisite for effective treatment. Both direct DNA damage and
sensitization to external beam radiotherapy should be increased by
prolonged administration of [125I]IUdR. Further improvements to
the biodegradable implant system are required to ensure adequate,
sustained delivery of drug. The systemic biodistribution of
labelled iodine after local delivery suggests that this approach to
treatment is likely to carry minimal toxicity. These findings are
extremely encouraging for the development of a sustained release
system for radiolabelled IUdR for use in the treatment of intracra-
nial tumours particularly in the immediate post-operative setting.
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